Inovio Pharmaceuticals Down; Bank of America Initiates at 'Neutral'
Inovio Pharmaceuticals Down; Bank of America Initiates at 'Neutral'
DJ Inovio Pharmaceuticals Down; Bank of America Initiates at 'Neutral'
By Michael Dabaie
Inovio Pharmaceuticals Inc. shares were down 6%, to $9.71, in Tuesday afternoon trading.
Bank of America initiated coverage on Inovio with a "Neutral" rating and $13 price objective.
"While we see potential from Inovio's DNA medicines pipeline, we see significant COVID-19 value baked into the stock," Bank of America said.
Bank of America said that while much of the Inovio debate has become linked to its Covid-19 vaccine INO-4800, the firm sees Inovio's pipeline of DNA-based medicines for indications that include other infectious diseases, HPV-related precancers, and oncology as bigger value drivers.
"INO-4800 contributes a significant portion of our [sum-of-the-parts net present value] and volatility around the C-19 vaccine landscape is what keeps us at a Neutral rating," Bank of America said.
"We aren't negative on the clinical profile of INO-4800 vs. competition, but rather, we see the C-19 vaccine market as increasingly saturated, with little room for upside for a later market entrant," the analyst note said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
March 23, 2021 14:28 ET (18:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
DJ Inovio Pharmaceuticals Down; Bank of America Initiates at 'Neutral'
DJ Inovio製藥公司股價下跌；美國銀行啟動“中性”計劃
By Michael Dabaie
邁克爾·達拜(Michael Dabaie)著
Inovio Pharmaceuticals Inc. shares were down 6%, to $9.71, in Tuesday afternoon trading.
在週二下午的交易中，Inovio PharmPharmticals Inc.的股價下跌了6%，至9.71美元。
Bank of America initiated coverage on Inovio with a "Neutral" rating and $13 price objective.
美國銀行(Bank Of America)對Inovio的覆蓋範圍為“中性”，目標價為13美元。
"While we see potential from Inovio's DNA medicines pipeline, we see significant COVID-19 value baked into the stock," Bank of America said.
美國銀行表示：“雖然我們從英諾威的基因藥物管道中看到了潛力，但我們也看到了新冠肺炎的巨大價值。”
Bank of America said that while much of the Inovio debate has become linked to its Covid-19 vaccine INO-4800, the firm sees Inovio's pipeline of DNA-based medicines for indications that include other infectious diseases, HPV-related precancers, and oncology as bigger value drivers.
美國銀行表示，雖然英諾威的大部分爭論都與其新冠肺炎疫苗INO-4800型有關，但該公司認為英諾威的dna藥物流水線將用於治療其他傳染病、人乳頭瘤病毒相關的癌症前病變和腫瘤學等更大的價值驅動因素。
"INO-4800 contributes a significant portion of our [sum-of-the-parts net present value] and volatility around the C-19 vaccine landscape is what keeps us at a Neutral rating," Bank of America said.
“INO-4800貢獻了我們的很大一部分[各部分之和淨現值]而圍繞C-19疫苗前景的波動性使我們保持中性評級。“美國銀行説。
"We aren't negative on the clinical profile of INO-4800 vs. competition, but rather, we see the C-19 vaccine market as increasingly saturated, with little room for upside for a later market entrant," the analyst note said.
“我們對INO-4800與競爭對手的臨牀情況並不持負面看法，相反，我們認為C-19疫苗市場正日益飽和，對於較晚的市場進入者幾乎沒有上升空間，”這份分析師報告説。
Write to Michael Dabaie at michael.dabaie@wsj.com
寫信給Michael Dabaie，電子郵件：michael.dabaie@wsj.com
(END) Dow Jones Newswires
(完)道瓊通訊社
March 23, 2021 14:28 ET (18:28 GMT)
2021年3月23日14：28美國東部時間(格林尼治標準時間18：28)
Copyright (c) 2021 Dow Jones & Company, Inc.
版權所有(C)2021年道瓊斯公司
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧